Arrowhead Pharma Files DEF 14A on Executive Compensation
Ticker: ARWR · Form: DEF 14A · Filed: Jan 29, 2025 · CIK: 879407
Sentiment: neutral
Topics: executive-compensation, corporate-governance, annual-meeting
TL;DR
Arrowhead Pharma's DEF 14A is out, detailing exec pay and equity awards for FY24. Check the numbers.
AI Summary
Arrowhead Pharmaceuticals, Inc. filed a DEF 14A on January 29, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending September 30, 2024. The filing includes information on equity awards granted to both principal executive officers (PEO) and non-principal executive officers (Non-PEO NEOs) for the fiscal years 2022, 2023, and 2024, with specific data points for equity awards in summary compensation tables.
Why It Matters
This filing provides transparency into how Arrowhead Pharmaceuticals compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and corporate governance, not indicating any immediate operational or financial risks.
Key Numbers
- 2024 — Fiscal Year End (The filing covers executive compensation data up to the fiscal year ending September 30, 2024.)
- 2023 — Fiscal Year End (The filing includes comparative executive compensation data for the fiscal year ending September 30, 2023.)
- 2022 — Fiscal Year End (The filing includes comparative executive compensation data for the fiscal year ending September 30, 2022.)
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — Filer of the DEF 14A
- 0001628280-25-002848 (filing_id) — Accession number for the filing
- 20250129 (date) — Filing date
- 0930 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide information to shareholders regarding the company's annual meeting, including details on executive compensation, director nominations, and corporate governance.
What specific fiscal years are covered by the compensation data in this filing?
The compensation data presented in this filing covers the fiscal years ending September 30, 2024, 2023, and 2022.
What types of equity awards are detailed in the filing?
The filing details equity awards granted to both Principal Executive Officers (PEO) and Non-Principal Executive Officers (Non-PEO NEOs), as presented in summary compensation tables.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on January 29, 2025.
What is the company's standard industrial classification?
The company's standard industrial classification is Pharmaceutical Preparations [2834].
Filing Stats: 4,603 words · 18 min read · ~15 pages · Grade level 13.6 · Accepted 2025-01-28 17:33:00
Key Financial Figures
- $15,000 — citation campaign is estimated at about $15,000. Proxies may also be solicited by certa
Filing Documents
- arwr-20250128.htm (DEF 14A) — 1014KB
- arwr-20250128_g1.jpg (GRAPHIC) — 38KB
- arwr-20250128_g10.jpg (GRAPHIC) — 322KB
- arwr-20250128_g2.jpg (GRAPHIC) — 66KB
- arwr-20250128_g3.jpg (GRAPHIC) — 53KB
- arwr-20250128_g4.jpg (GRAPHIC) — 49KB
- arwr-20250128_g5.jpg (GRAPHIC) — 20KB
- arwr-20250128_g6.jpg (GRAPHIC) — 89KB
- arwr-20250128_g7.jpg (GRAPHIC) — 147KB
- arwr-20250128_g8.jpg (GRAPHIC) — 115KB
- arwr-20250128_g9.jpg (GRAPHIC) — 431KB
- 0001628280-25-002848.txt ( ) — 4825KB
- arwr-20250128.xsd (EX-101.SCH) — 1KB
- arwr-20250128_htm.xml (XML) — 136KB
Executive Compensation
Executive Compensation 22 Compensation Discussion and Analysis 22 Our Company 22 Business Development 23 Platform 24 Pipeline 25
Executive Compensation Philosophy
Executive Compensation Philosophy 33
Executive Compensation Program Design
Executive Compensation Program Design 33 Governance of Executive Compensation Program 34 Individual Compensation Elements 36 Employment Arrangements 41 Post-Employment Compensation Arrangements 41 Other Compensation Policies and Practices 41 Tax and Accounting Considerations 42 Compensation Risk Assessment 43 Compensation Tables 44 Proposal Four — Ratification of Appointment of Independent Auditors 58 Audit Fees 59 Report of the Audit Committee 60 Voting Securities of Principal Stockholders and Management 61 Equity Compensation Plan Information 63 Review and Approval of Related-Party Transactions 65 Certain Relationships and Related Transactions, and Director Independence 66 Table of Contents 2025 PROXY STATEMENT General Information Concerning Solicitation and Voting ARROWHEAD PHARMACEUTICALS, INC. 177 E. Colorado Blvd., Suite 700 Pasadena, California 91105 (626) 304-3400 PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS To be held on Wednesday, March 12, 2025 General Information Concerning Solicitation and Voting The enclosed Proxy is solicited on behalf of Arrowhead Pharmaceuticals, Inc. (the " Company " or " Arrowhead ") for use at the 2025 Annual Meeting of Stockholders (the " Annual Meeting ") to be held on Wednesday, March 12, 2025 at 10:00 a.m., Pacific time, and at any adjournment(s) or postponement(s) thereof, for the purposes set forth herein and in the accompanying Notice of Annual Meeting of Stockholders (the " Notice "). The Company anticipates that the Notice Regarding the Availability of Proxy Materials (the " Notice of Internet Availability ") in connection with these proxy solicitation materials will first be mailed on or about January 28, 2024 to all stockholders entitled to vote at the Annual Meeting and we will post our proxy materials on the website referenced in the Notice of Internet Availability. As more fully described in the Notice of Internet Availability, all stockholders may c